The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management

por Denault, Marie-Helene, Ho, Cheryl
Publicado 2023

Immunotherapy in the First-Line Setting in Wild-Type NSCLC

por Denault, Marie-Hélène, Melosky, Barbara
Publicado 2021

Wait Times and Survival in Lung Cancer Patients across the Province of Quebec, Canada

por Denault, Marie-Hélène, Labbé, Catherine, St-Pierre, Carolle, Fournier, Brigitte, Gagné, Andréanne, Morillon, Claudia, Joubert, Philippe, Simard, Serge, Martel, Simon
Publicado 2022

Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report

por Denault, Marie-Hélène, Kuang, Shelley, Shokoohi, Aria, Leung, Bonnie, Liu, Mitchell, Berthelet, Eric, Laskin, Janessa, Sun, Sophie, Zhang, Tina, Melosky, Barbara, Ho, Cheryl
Publicado 2022

Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression

por Denault, Marie-Hélène, Feng, Jamie, Kuang, Shelley, Shokoohi, Aria, Leung, Bonnie, Liu, Mitchell, Berthelet, Eric, Laskin, Janessa, Sun, Sophie, Zhang, Tina, Ho, Cheryl, Melosky, Barbara
Publicado 2023